BECOME A STUDY PARTICIPANT

Individuals who participate in our research studies are vital to the mission of PRISM. If you are interested in becoming a participant in one of our research studies,
learn more about different opportunities below.

ALL STUDIES ARE CONDUCTED BY WASHINGTON STATE UNIVERSITY.

Take a quiz to see which studies may be a good fit for you!

Individualizing Incentives to Maximize Recovery

If you use alcohol, have a mental health disorder, are aged 18-65, and want to cut down or stop using alcohol, then you might be a good fit for this study! Participants in this study will receive gift cards for their participation and for providing alcohol-negative urine samples.

Image by Visual Stories || Micheile

LOCATION: Spokane & Seattle, WA

STATUS: Currently Recruiting

Image by Joanna Kosinska

Zonisamide for the Treatment of Alcohol Use Disorder in the Addiction Neuroclinical Assessment Framework (ZARRA)

Washington State University and The Community Health Association of Spokane (CHAS) are partnering to conduct a study evaluate the ability of a medication called zonisamide to decrease alcohol use among treatment-seeking adults with an alcohol use disorder.

LOCATION: Spokane, WA

STATUS: Currently Recruiting

Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking (PERRAS)

Washington State University is partnering with Recovery Centers, Oregon Recovery and Treatment Centers and Range Community Clinic to conduct a study to evaluate the ability of evidence based behavioral treatment, called contingency management, to decrease alcohol use and cigarette smoking among treatment-seeking smokers with an alcohol use disorder who have initiated varenicline (Chantix) for smoking cessation.

Doctor's Desk

LOCATION: Spokane, WA

STATUS: Currently Recruiting

White Pills

 Mobile Medication Adherence Platform for Buprenorphine-Naloxone (MAP4BUP) During Treatment of Opioid Use Disorder

Washington State University, Pillsy Inc, and Ideal Option are partnering to conduct a study that will use a connected smart pill bottle cap and mobile technology to see if it can improve care.

LOCATION: Spokane, WA

STATUS: Coming Soon

Management to Reduce Heavy Alcohol Drinking Days Among Smokers Receiving Varenicline Treatment (CM4HDS) 

Washington State University and The Community Health Association of Spokane (CHAS) are partnering to conduct a study to evaluate the ability of a well-studied behavioral intervention method, called contingency management, to decrease alcohol use and cigarette smoking among treatment-seeking smokers with an alcohol use disorder who have initiated varenicline (Chantix) for smoking cessation.

Notepad on Desk

LOCATION: Spokane, WA

STATUS: Currently Recruiting

Image by Visual Stories || Micheile

Individualizing Incentives to Maximize Recovery

Washington State University is recruiting people aged 18-65 who have schizophrenia, schizoaffective, bipolar or major depressive disorder and want to cut down or stop using alcohol for a study in Seattle and Spokane, WA.

This study is examining a behavioral intervention, called contingency management, to help individuals reduce their alcohol use and initiate abstinence.

Study participants receive gift cards as rewards for providing alcohol-negative urine and breath samples as well as gift cards for their participation. Participants will receive Contingency Management at no cost. The study requires participants to attend 15-60 minute visits 2x/week for 20 weeks at our Sound (Seattle) or WSU Research Clinic (Spokane) locations. At visits, participants will provide urine samples and answer questionnaires, with 4 follow up visits over the course of a year.

If you are interested in learning more about the study and to find out if you are eligible, please call 206-566-3601 (Seattle) or 509-496-5325 (Spokane) or fill out the contact information sheet below and we will contact you.

Currently recruiting; anticipated end date November 2024

 
Image by Joanna Kosinska

Zonisamide for
the Treatment
of Alcohol Use Disorder in the Addiction Neuroclinical Assessment Framework (ZARRA)

Participants will be asked to take a medication (either zonisamide
or matching placebo) over a period of 14 weeks at a dosing schedule that is consistent with best practices for zonisamide. They will be asked to fill out questionnaires, watch educational modules, and complete a urinalysis during the study visits. Participation will involve three visits per week from weeks 1-6, one visit per week from weeks 7-14, and three visits total at weeks 18, 27, and 54. Eligibility for this study includes being between the ages 18-65, having four or more standard drinks on four or more occasions in the prior 30 days, be non-pregnant or lactating, and currently seeking alcohol use disorder treatment. Participants may receive up to approximately $463 in virtual gift cards over the course of the study.

Currently recruiting; anticipated end date July 2025

 
Doctor's Desk

Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking (PERRAS)

Participants will be asked take varenicline for a 12-week treatment period. They will be asked to watch educational modules, fill out questionnaires and complete a urinalysis during the study visits. Participation will involve three visits per week from weeks 1-14 and three visits total at weeks 18, 27, and 54. Eligibility for this study includes ≥ 18 years of age, having four or more standard drinks on four or more occasions in the prior 30 days, and currently seeking alcohol use disorder and smoking cessation treatment. Participants may receive up to approximately $600 in virtual gift cards over the course of the study.

Currently recruiting; anticipated end date March 2025

 
White Pills

 Mobile Medication Adherence Platform for Buprenorphine-Naloxone (MAP4BUP) During Treatment of Opioid Use Disorder

Participants will be asked to use a smart pill bottle cap connected to mobile technology that can help remind them to take the medication as prescribed. They will also be asked to fill out questionnaires during the study visit. Participation in this study will involve four office visits over 12 weeks and responding to reminders on your Smartphone. Eligibility for this study includes ≥ 18 years of age, having a Smartphone or other device that can accept data messages, and a current suboxone treatment regimen. Participants may receive up to four $50 Walmart gift cards.

Anticipated start date June 1, 2022; end date July 31, 2024

 
Notepad on Desk

Management to Reduce Heavy Alcohol Drinking Days Among Smokers Receiving Varenicline Treatment (CM4HDS) 

Participants will be asked to use a phone application that monitors smoking and alcohol use. They will be asked to submit breathalyzer samples, complete saliva samples, and fill out questionnaires at study visits. Participation will involve weekly study visits for a 9-week treatment period. Eligibility for this study includes ≥ 21 years of age, currently receiving varenicline treatment 6 weeks prior to study initiation, and currently seeking alcohol use disorder treatment. Participants may receive up to approximately $670 in virtual gift cards over the course of the study.

Currently recruiting; anticipated end date
July 1, 2025